O
OPK
Opko Health
1.15
0.01+0.44%Opening13:11 04/01 EDT
OPEN/PREV CLOSE1.160/1.140
TODAY RANGE1.140-1.160
VOL668.80K
MARKET CAP869.13M
52 WEEK RANGE1.095-1.690
AVG VOL (3M)2.88M
% TURNOVER0.09%
TURNOVER--
P/E (TTM)-3.8103
% RANGE1.75%
EPS(TTM)-0.3005
P/E(FORWARD)-4.0893
P/B0.6855
BVPS1.670
DIVIDEND--
P/S1.432
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP440.97M
SHARES OUTSTANDING759.07M
NEXT EARNINGS04/28-05/04
FREE FLOAT385.13M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
Seeking Alpha·6d ago
OPKO Health: The Waiting Game Continues
TipRanks·03/21 13:01
Opko, Prologis, Williams, APA, Paysafe: Insider Moves Exposed
TipRanks·03/19 21:19
Opko Health Adds Independent Director to Strengthen Governance
Reuters·03/19 20:50
Opko Health appoints Subbarao V. Uppaluri as director
Reuters·03/19 02:43
Vesicor Therapeutics names Michael Tolentino CEO as Luo Feng becomes CSO
Dow Jones·03/02 15:54
OPKO Health Is Maintained at Outperform by Barrington Research
Dow Jones·03/02 15:54
OPKO Health Price Target Cut to $1.50/Share From $2.25 by Barrington Research
TipRanks·03/02 14:20
Opko Health price target lowered to $1.50 from $2.25 at Barrington
TipRanks·03/02 11:39
H.C. Wainwright Reaffirms Their Buy Rating on Opko Health (OPK)
Simply Wall St·02/28 01:30
OPKO Health (OPK) Loss Worsens To US$0.30 TTM EPS Challenging Turnaround Narratives
TipRanks·02/28 00:11
Opko Health Bets on Pipeline as Near-Term Profits Fade
TipRanks·02/27 13:16
Ladenburg Thalmann & Co. Sticks to Its Buy Rating for Opko Health (OPK)
TipRanks·02/27 13:03
Piper Sandler Sticks to Its Buy Rating for Opko Health (OPK)
Reuters·02/27 13:01
OPKO Health to Participate in Jefferies Biotech on the Beach Summit
Same Industry
Name/Symbol
Change%
Price
Contact Us
Contact Number :+852 3852 8500Monday 7:00 AM - Saturday 9:00 AM (HKT)
Service Email :service@webull.hkOnline Support: Monday - Friday: 9:00 - 16:00; 22:30 - 5:00 (HKT)
Business Cooperation :marketinghk@webull.hkRisk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language
English
©2026 Webull Securities Limited. All rights reserved.